SCHEMBL10003449

SCHEMBL10003449

CCOC(=O)c1c(OCC(F)(F)F)c2nc(-c3ccc(F)cc3)c(CC)nc2n1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA2 P47869 2/20 0.44
▸ GABRB2 P47870 2/20 0.44
▸ ALDH1A1 P00352 6/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ KDM4E B2RXH2 4/20 0.41
▸ HPGD P15428 4/20 0.41
▸ LMNA P02545 1/20 0.41
▸ GAA P10253 1/20 0.40
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ MAPT P10636 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ ALOX5 P09917 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003837 0.92 GABRA2 (0.43) GABRA2GABRB2ALDH1A1KDM4EHPGD
SCHEMBL10003341 0.90 GRIA2 (0.38) GABRA2GABRB2ALDH1A1L3MBTL1KDM4E
SCHEMBL10003388 0.85 GABRA2 (0.45) GABRA2GABRB2ALDH1A1L3MBTL1KDM4E
SCHEMBL10003266 0.83 GABRA2 (0.49) GABRA2GABRB2ALDH1A1L3MBTL1KDM4E
SCHEMBL10003348 0.83 ALDH1A1 (0.44) GABRA2GABRB2ALDH1A1L3MBTL1KDM4E
SCHEMBL10004308 0.82 CYP1A2 (0.44) GABRA2GABRB2ALDH1A1KDM4EHPGD
SCHEMBL10003232 0.82 CACNA1G (0.35) GABRA2GABRB2CYP1A2CYP2C9CYP2C19
SCHEMBL10003768 0.78 SMO (0.49) HSD17B10
SCHEMBL10004349 0.78 HTT (0.44) ALDH1A1KDM4EHPGDLMNAGAA
SCHEMBL10003062 0.77 LMNA (0.46) ALDH1A1L3MBTL1KDM4EHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH GABRA2 2197/4885GABRB2 1779/4885ALDH1A1 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback